Literature DB >> 9454808

Neuropeptide Y attenuates naloxone-precipitated morphine withdrawal via Y5-like receptors.

D P Woldbye1, K Klemp, T M Madsen.   

Abstract

The effects of intracerebroventricular injection of neuropeptide Y (NPY) and various NPY-related peptides were studied on naloxone-precipitated withdrawal from morphine in rats. The withdrawal reaction was assessed using an overall motor score, including jumping, wet dog shakes and other motor-related signs as well as a nonmotor score. At doses of 3, 6 or 12 nmol, NPY strongly and dose-dependently reduced the motor score. A less prominent inhibitory effect was revealed on the nonmotor score. At 6 nmol, [Leu31,Pro34]-NPY, NPY 3-36, peptide YY and human pancreatic polypeptide all significantly attenuated the motor score, whereas NPY 13-36 was without effect. This pharmacological profile suggests that the antiwithdrawal effect of NPY is mediated via the recently cloned Y5 receptor. Our data are consistent with a potential role for NPY and Y5-like receptors in basic mechanisms and as a therapeutic target in opioid dependence and withdrawal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454808

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Molecular identification of the long isoform of the human neuropeptide Y Y5 receptor and pharmacological comparison with the short Y5 receptor isoform.

Authors:  Marianne Rodriguez; Valérie Audinot; Sandra Dromaint; Christelle Macia; Véronique Lamamy; Philippe Beauverger; Hervé Rique; Jérôme Imbert; Jean Paul Nicolas; Jean A Boutin; Jean Pierre Galizzi
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

Review 2.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

3.  Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats.

Authors:  Daria Rylkova; Jeffrey Boissoneault; Shani Isaac; Melissa Prado; Hina P Shah; Adrie W Bruijnzeel
Journal:  Neuropeptides       Date:  2008-05-12       Impact factor: 3.286

Review 4.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 5.  Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides.

Authors:  Nicole M Enman; Yong Zhang; Ellen M Unterwald
Journal:  Pharmacol Biochem Behav       Date:  2013-12-11       Impact factor: 3.533

6.  A role for neuropeptide Y Y5 but not the Y1-receptor subtype in food deprivation-induced reinstatement of heroin seeking in the rat.

Authors:  Tia Maric; Firas Sedki; Danielle Chafetz; Nick Schoela; Uri Shalev
Journal:  Psychopharmacology (Berl)       Date:  2011-06-01       Impact factor: 4.530

Review 7.  Neuropeptide systems and new treatments for nicotine addiction.

Authors:  Adriaan W Bruijnzeel
Journal:  Psychopharmacology (Berl)       Date:  2016-12-28       Impact factor: 4.530

Review 8.  A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors.

Authors:  Riley Merkel; Amanda Moreno; Yafang Zhang; Rachel Herman; Jennifer Ben Nathan; Sana Zeb; Suditi Rahematpura; Kamryn Stecyk; Brandon T Milliken; Matthew R Hayes; Robert P Doyle; Heath D Schmidt
Journal:  Neurosci Biobehav Rev       Date:  2021-10-29       Impact factor: 8.989

Review 9.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

10.  Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression.

Authors:  B Mayer-Blackwell; S D Schlussman; E R Butelman; A Ho; J Ott; M J Kreek; Y Zhang
Journal:  Neuroscience       Date:  2013-11-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.